Lan, M., Wang, T., Luo, D., Chen, Y., Liang, W., Kong, R., & Xie, Q. Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpression. Frontiers Media S.A.
Chicago Style (17th ed.) CitationLan, Meiling, Tianyun Wang, Diexiao Luo, Yan Chen, Wei Liang, Rui Kong, and Qichao Xie. Application of Disitamab Vedotin in the Multiline Treatment of EGFR Mutation-positive Lung Adenocarcinoma with Her-2 Overexpression. Frontiers Media S.A.
MLA (9th ed.) CitationLan, Meiling, et al. Application of Disitamab Vedotin in the Multiline Treatment of EGFR Mutation-positive Lung Adenocarcinoma with Her-2 Overexpression. Frontiers Media S.A.
Warning: These citations may not always be 100% accurate.